About Us
Overview
Business Model
Milestones
Our Presence
Board of Directors
Committees of Board
Management Team
Corporate Governance Report
Mission, Vision & Values
Environment
At Granules, we are proud to have maintained a record of sucess since 1984. The milestones that have catalysed our growth are indicated below:

  • 1984: Inception of Triton Laboratories at Bonthapally for manufacture of Paracetamol/Acetaminophen API.

  • 1990: Established a multi-active facility at Jeedimetla.

  • 1991: Formation of Granules India Limited.

  • 1993: Established a small volume PFI facility at Jeedimetla with a plant capacity of 1,440 TPA.

  • 1995: Announced our Initial Public Offering (IPO).

  • 1998: Expansion of Jeedimetla facility for development of Guaifenesin and Metformin APIs.

  • 2001: Obtained U.S. FDA & cGMP approval for PFIs and other APIs at the Jeedimelta facility.

  • 2002: Developed new Guaifensin, Metformin and Ibuprofen PFIs.

  • 2003: Opened a large volume PFI facility at Gagillapur with a capacity of 7,200 TPA.

  • 2003: Set up a wholly-owned subsidiary in the U.S. called Granules USA Inc., for marketing and logistics.

  • 2004: Obtained approval from U.S. FDA, Australian TGA and German Health Authority for our PFI plant at Gagillapur.

  • 2005: Built a new manufacturing facility for Paracetamol/Acetaminophen API.

  • 2006: Joint venture with Hubei Biocause Pharmaceutical Co. LTD, in Wuhan, China to manufacture and sell Ibuprofen API.

  • 2008: Commenced a six billion tablet facility at Gagillapur after receiving approval from the European Regulatory Body
    in October 2008.

  • 2010: Received U.S.FDA Approval on our dedicated finished dosage facility at Gagillapur.